<p>拜玛林制药（NASDAQ:BMRN - 获取免费报告）在周三早上发布了关于其 2024 财年盈利指引的更新。公司为该期间提供了每股盈利指引为 3.10 美元至 3.25 美元，相比之下，市场预期每股盈利为 3.23 美元。公司发布了总收入指引为 27.50 亿美元至 28.25 亿美元，相比之下，市场预期总收入为 28.00 亿美元。</p>
<h2>拜玛林制药股价表现</h2>
<ul>
<li>基因疗法股票是否是市场的下一个大赢家？</li>
</ul>
<p>拜玛林制药股票周三交易中下跌 1.22 美元，报 90.38 美元。该股交易量为 1,217,338 股，相比平均交易量 1,827,818 股。该股市值为 171.6 亿美元，市盈率为 85.60，β系数为 0.32。拜玛林制药的 52 周最低价为 73.68 美元，52 周最高价为 99.56 美元。公司的速动比率为 1.95，流动比率为 3.05，负债权益比为 0.11。该公司的 50 日移动平均价为 86.37 美元，200 日移动平均价为 85.06 美元。</p>
<p>拜玛林制药（NASDAQ:BMRN - 获取免费报告）上次公布财报是在 8 月 5 日星期一。这家生物技术公司报告该季度每股盈利为 0.77 美元，超过分析师预期的 0.38 美元。该季度营收为 7.1203 亿美元，超过分析师预期的 6.6051 亿美元。拜玛林制药的净利润率为 9.91%，净资产收益率为 6.91%。研究分析师预计，拜玛林制药本财年将实现每股盈利 2.35 美元。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>拜玛林在 FDA 批准 Roctavian 后准备反弹吗？</li>
</ul>
<p>一些股票研究分析师最近对该股发表了评论。Scotiabank 将拜玛林制药的目标股价从 85.00 美元上调至 86.00 美元，并在 8 月 6 日星期二的报告中给予该公司一个行业表现评级。Robert W. Baird 将拜玛林制药的评级从跑赢市场下调为中性评级，并在 5 月 17 日星期五的研究报告中将股票的目标价从 104.00 美元下调至 72.00 美元。Stifel Nicolaus 将拜玛林制药的目标股价从 112.00 美元上调至 115.00 美元，并在 8 月 21 日星期三的研究报告中给予该公司买入评级。Baird R W 将拜玛林制药的评级从强热门股票下调为持有评级，并在 5 月 17 日星期五的研究报告中给出这一调整。最后，Evercore ISI 将拜玛林制药的目标价从 113.00 美元上调至 115.00 美元，并在 8 月 6 日星期二的研究报告中给予该股一项跑赢市场评级。八位研究分析师对该股给出持有评级，十四位对该公司给出买入评级。根据 MarketBeat 的数据，该股目前的共识评级为中等买入，平均目标价为 105.26 美元。</p>
<p><strong>阅读我们关于拜玛林制药的最新股票报告</strong></p>
<h2>关于拜玛林制药（获取免费报告）</h2>
<ul>
<li>顶级生物技术股票：探索创新机会</li>
</ul>
<p>拜玛林制药公司开发和销售用于治疗严重和危及生命的罕见疾病和医疗状况的疗法。其商业产品包括 Vimizim，用于治疗粘多糖沉积症（MPS）IV 型 A 的酶替代疗法，这是一种溶酶体贮积症；Naglazyme，用于治疗 MPS VI 患者的重组 N-乙酰半乳糖胺 4-磺酸酶；以及 Kuvan，一种用于治疗苯丙酮尿症（PKU）患者的合成口服 6R-BH4 的专有药物。</p>
<h2>精选文章</h2>
<ul>
<li>我们比拜玛林制药更喜欢的五只股票</li>
<li>ETF 是否支付股息？你需要了解的</li>
<li>为什么迪克可能成为你投资组合的一大亮点</li>
<li>投资者如何从盘后交易中受益</li>
<li>斐波那契回撤水平简介</li>
<li>什么是股息收割策略，投资者如何从中获利？</li>
<li>在市场下跌中表现优于标普 500 指数的前三只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg"/></p>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 我对人工智能股票的严峻警告（来自 Porter &amp; Company）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjUy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjUy"/></p>
<h2>现在是否值得投资 1,000 美元购买拜玛林制药？</h2>
<p>在考虑投资拜玛林制药之前，您需要听到这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而拜玛林制药不在这份名单上。</p>
<p>尽管拜玛林制药目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

拜玛林制药

<p>BioMarin Pharmaceutical（纳斯达克股票代码：BMRN）已更新其 2024 财年盈利指引，预计每股收益在 0.10 美元至 0.25 美元之间，与市场预期的 0.23 美元形成对比。营收指引为 7.5 亿美元至 8.25 亿美元，而市场预期为 8 亿美元。该公司最近公布的季度每股收益为 0.77 美元，超出预期。股价最近略有下跌，继续反映出分析师对其持有中度买入评级，共识价格目标为 81.26 美元</p>

<p>BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $3.10-$3.25 for the period, compared to the consensus earnings per share estimate of $3.23. The company issued revenue guidance of $2.750-$2.825 billion, compared to the consensus revenue estimate of $2.80 billion.</p>
<div class="lb-trans"><p>拜玛林制药（NASDAQ:BMRN - 获取免费报告）在周三早上发布了关于其 2024 财年盈利指引的更新。公司为该期间提供了每股盈利指引为 3.10 美元至 3.25 美元，相比之下，市场预期每股盈利为 3.23 美元。公司发布了总收入指引为 27.50 亿美元至 28.25 亿美元，相比之下，市场预期总收入为 28.00 亿美元。</p>
</div><h2>BioMarin Pharmaceutical Price Performance</h2>
<ul>
<li>Are Gene Therapy Stocks The Market's Next Big Winners?</li>
</ul>
<div class="lb-trans"><h2>拜玛林制药股价表现</h2>
<ul>
<li>基因疗法股票是否是市场的下一个大赢家？</li>
</ul>
</div><p>Shares of BioMarin Pharmaceutical stock traded down $1.22 during trading on Wednesday, hitting $90.38. 1,217,338 shares of the stock traded hands, compared to its average volume of 1,827,818. The stock has a market cap of $17.16 billion, a price-to-earnings ratio of 85.60 and a beta of 0.32. BioMarin Pharmaceutical has a 52 week low of $73.68 and a 52 week high of $99.56. The company has a quick ratio of 1.95, a current ratio of 3.05 and a debt-to-equity ratio of 0.11. The firm's fifty day moving average is $86.37 and its 200-day moving average is $85.06.</p>
<div class="lb-trans"><p>拜玛林制药股票周三交易中下跌 1.22 美元，报 90.38 美元。该股交易量为 1,217,338 股，相比平均交易量 1,827,818 股。该股市值为 171.6 亿美元，市盈率为 85.60，β系数为 0.32。拜玛林制药的 52 周最低价为 73.68 美元，52 周最高价为 99.56 美元。公司的速动比率为 1.95，流动比率为 3.05，负债权益比为 0.11。该公司的 50 日移动平均价为 86.37 美元，200 日移动平均价为 85.06 美元。</p>
</div><p>BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its earnings results on Monday, August 5th. The biotechnology company reported $0.77 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.39. The business had revenue of $712.03 million during the quarter, compared to analysts' expectations of $660.51 million. BioMarin Pharmaceutical had a net margin of 9.91% and a return on equity of 6.91%. Research analysts expect that BioMarin Pharmaceutical will post 2.35 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>拜玛林制药（NASDAQ:BMRN - 获取免费报告）上次公布财报是在 8 月 5 日星期一。这家生物技术公司报告该季度每股盈利为 0.77 美元，超过分析师预期的 0.38 美元。该季度营收为 7.1203 亿美元，超过分析师预期的 6.6051 亿美元。拜玛林制药的净利润率为 9.91%，净资产收益率为 6.91%。研究分析师预计，拜玛林制药本财年将实现每股盈利 2.35 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<ul>
<li>Is BioMarin Ready To Rebound After FDA Approval Of Roctavian?</li>
</ul>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
<ul>
<li>拜玛林在 FDA 批准 Roctavian 后准备反弹吗？</li>
</ul>
</div><p>A number of equities research analysts have recently commented on the stock. Scotiabank upped their price objective on shares of BioMarin Pharmaceutical from $85.00 to $86.00 and gave the company a sector perform rating in a report on Tuesday, August 6th. Robert W. Baird downgraded BioMarin Pharmaceutical from an outperform rating to a neutral rating and dropped their price target for the stock from $104.00 to $72.00 in a research report on Friday, May 17th. Stifel Nicolaus upped their price objective on shares of BioMarin Pharmaceutical from $112.00 to $115.00 and gave the company a buy rating in a research note on Wednesday, August 21st. Baird R W lowered BioMarin Pharmaceutical from a strong-buy rating to a hold rating in a research note on Friday, May 17th. Finally, Evercore ISI upped their price target on BioMarin Pharmaceutical from $113.00 to $115.00 and gave the stock an outperform rating in a research note on Tuesday, August 6th. Eight research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $105.26.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对该股发表了评论。Scotiabank 将拜玛林制药的目标股价从 85.00 美元上调至 86.00 美元，并在 8 月 6 日星期二的报告中给予该公司一个行业表现评级。Robert W. Baird 将拜玛林制药的评级从跑赢市场下调为中性评级，并在 5 月 17 日星期五的研究报告中将股票的目标价从 104.00 美元下调至 72.00 美元。Stifel Nicolaus 将拜玛林制药的目标股价从 112.00 美元上调至 115.00 美元，并在 8 月 21 日星期三的研究报告中给予该公司买入评级。Baird R W 将拜玛林制药的评级从强热门股票下调为持有评级，并在 5 月 17 日星期五的研究报告中给出这一调整。最后，Evercore ISI 将拜玛林制药的目标价从 113.00 美元上调至 115.00 美元，并在 8 月 6 日星期二的研究报告中给予该股一项跑赢市场评级。八位研究分析师对该股给出持有评级，十四位对该公司给出买入评级。根据 MarketBeat 的数据，该股目前的共识评级为中等买入，平均目标价为 105.26 美元。</p>
</div><p><strong>Read Our Latest Stock Report on BioMarin Pharmaceutical</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于拜玛林制药的最新股票报告</strong></p>
</div><h2>About BioMarin Pharmaceutical (Get Free Report)</h2>
<ul>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
</ul>
<div class="lb-trans"><h2>关于拜玛林制药（获取免费报告）</h2>
<ul>
<li>顶级生物技术股票：探索创新机会</li>
</ul>
</div><p>BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.</p>
<div class="lb-trans"><p>拜玛林制药公司开发和销售用于治疗严重和危及生命的罕见疾病和医疗状况的疗法。其商业产品包括 Vimizim，用于治疗粘多糖沉积症（MPS）IV 型 A 的酶替代疗法，这是一种溶酶体贮积症；Naglazyme，用于治疗 MPS VI 患者的重组 N-乙酰半乳糖胺 4-磺酸酶；以及 Kuvan，一种用于治疗苯丙酮尿症（PKU）患者的合成口服 6R-BH4 的专有药物。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than BioMarin Pharmaceutical</li>
<li>Do ETFs Pay Dividends? What You Need to Know</li>
<li>Why Dick’s Could Be a Slam Dunk for Your Investment Portfolio</li>
<li>How Can Investors Benefit From After-Hours Trading</li>
<li>Introduction to Fibonacci Retracement Levels</li>
<li>What is a Dividend Harvesting Strategy and How Can Investors Profit from it?</li>
<li>Top 3 Stocks to Outperform the S&amp;P 500 in a Downturn</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>我们比拜玛林制药更喜欢的五只股票</li>
<li>ETF 是否支付股息？你需要了解的</li>
<li>为什么迪克可能成为你投资组合的一大亮点</li>
<li>投资者如何从盘后交易中受益</li>
<li>斐波那契回撤水平简介</li>
<li>什么是股息收割策略，投资者如何从中获利？</li>
<li>在市场下跌中表现优于标普 500 指数的前三只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=BMRN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ My grim warning about AI stocks (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 我对人工智能股票的严峻警告（来自 Porter &amp; Company）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjUy" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9252&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in BioMarin Pharmaceutical right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1,000 美元购买拜玛林制药？</h2>
</div><p>Before you consider BioMarin Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资拜玛林制药之前，您需要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而拜玛林制药不在这份名单上。</p>
</div><p>While BioMarin Pharmaceutical currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管拜玛林制药目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

拜玛林制药（NASDAQ:BMRN）更新了 2024 财年的收益指引